Compare Novartis AG (NVS) vs Paychex, Inc. (PAYX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Paychex, Inc. — how do they compare? Novartis AG trades at $153.88 (market cap $290.25B), while Paychex, Inc. trades at $115.19 (market cap $40.98B). The key difference: Novartis AG is far larger — about 7.1× Paychex, Inc.'s market cap, and Paychex, Inc. pays the higher dividend (4.13%). Which is the better fit depends on your goals.
| NVS | PAYX | |
|---|---|---|
Market Cap | $290.25B | $40.98B |
Sector | Health | Industrials |
52-Week High | $168.62 | $147.99 |
52-Week Low | $113.50 | $85.57 |
Enterprise Value | $330.27B | $44.47B |
Dividend Yield | 3.17% | 4.13% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $153.87, showing minimal daily movement with a slight 0.07% gain. The stock exhibits bearish technical signals from moving averages despite a neutral oscillator reading. Fundamentally, the company reported strong Q2 2026 earnings that beat expectations, with revenue of $56.67 billion in 2025 and robust profitability margins, including a net income margin of 23.92%. Recent news highlights successful drug launches offsetting generic competition pressures.
The outlook remains cautiously optimistic as new medicines drive growth, but risks include patent expirations and pipeline trial results. Analyst sentiment is mixed with 68% hold ratings, reflecting balanced views on execution versus competitive threats. Investment appeal hinges on sustained drug innovation and margin stability amid industry headwinds.
Paychex (PAYX) trades at $111.96, down 2.12% on the day, with technical indicators showing a bullish trend despite overbought RSI readings. The company maintains strong profitability with 27.03% net margins and has beaten earnings estimates for three consecutive quarters. Recent dividend declarations of $1.19 per share and positive small business job growth data support the investment case.
The outlook remains positive with steady revenue growth and AI expansion driving future earnings. Key risks include macroeconomic headwinds affecting small business hiring and elevated valuation multiples. Analyst consensus is mixed with a $110 price target slightly below current levels, suggesting cautious optimism amid strong fundamentals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Paychex, Inc.
Paychex is a leading provider of payroll, human capital management, and insurance solutions servicing small and midsize clients primarily in the United States. The company, established in 1979, services over 730,000 clients and pays over 1 in 12 U.S. private-sector workers. Alongside its traditional payroll services, Paychex offers HCM solutions such as benefits administration and time and attendance software, as well as human resources outsourcing and insurance agency services.
Read more on PAYX →
